Supernus Pharma (SUPN) Tops Q3 EPS by 3c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/30/2026

1. NOW
2. GOOGL
3. MSFT
4. FTNT
5. EBAY
6. BIIB
7. CMG
8. TENB
9. KLAC
10. ETSY

Go back to Supernus Pharma (SUPN) Tops Q3 EPS by 3c

Supernus Announces Third Quarter 2014 Results

November 11, 2014 4:30 PM EST

The Company raises revenue guidance from approximately $105 million to a range of $115 million to $118 million for 2014 and reaffirms cash flow break even by end of year. Total revenue for the quarter, $52.5 million, includes $30.0 million in royalty monetization revenue. Net product revenue for the third quarter for Trokendi XR® and Oxtellar XR® was $22.5 million. Third quarter product prescriptions increased to a total of 57,776, representing a 26% increase over the second quarter of 2014. Third quarter net income was $27.9 million. Excluding the $30 million royalty monetization payment, cash burn for the third quarter was $5 million, as compared to $8... More